Dyshidrotic eczema is a common skin disease that probably accounts for about 5% to 20% of hand eczemas. Sometimes underlying trigger mechanisms can be detected, such as allergic contact dermatitis, dermatophytosis, bacterial foci, or drug eruptions, so that in these cases causal therapy can be applied. In the majority of cases, however, only symptomatic therapy can be offered, including the use of topical or systemic corticosteroids, phototherapy, and/or iontophoresis. Unfortunately, most of these attempts do not lead to long-term improvement and the majority of cases of dyshidrotic eczema relapse, persist for years, and still present a therapeutic problem. We describe a patient with dyshidrotic eczema that was resistant to conventional therapies but responded satisfactorily to the new immunosuppressive drug mycophenolate mofetil.
Pickenäcker A, Luger TA, Schwarz T. Dyshidrotic Eczema Treated With Mycophenolate Mofetil. Arch Dermatol. 1998;134(3):378–379. doi:
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: